%0 Journal Article
%T Comparing Outcomes of Trabeculectomy with Mitomycin C to 45 μm Gelatin Stent Placed Ab Externo with Open Conjunctiva
%A Sabogal E
%A Ingram Z
%A Odishelidze N
%A El Helwe H
%A Falah HK
%A Trzcinski J
%A Hall N
%A Solá-Del Valle D
%J Ophthalmol Glaucoma
%V 7
%N 3
%D 2024 May-Jun 4
%M 38056708
暂无%R 10.1016/j.ogla.2023.11.005
%X To compare trabeculectomy with mitomycin C (trab-MMC) and XEN45 Gel Stent placed ab externo with open conjunctiva (XGS AEO) with or without cataract surgery in patients with glaucoma.<BR>Nonrandomized, retrospective, comparative study.<BR>A total of 204 eyes from 204 glaucoma patients who received XGS AEO or underwent trab-MMC with or without cataract surgery between July 2018 and August 2021 at Massachusetts Eye and Ear.<BR>Visits from 204 patient charts were reviewed after either trab-MMC or XGS AEO from 2018 to 2021 from a level 3 triage center.<BR>Intraocular pressure (IOP), medication burden, Kaplan-Meier success rates, 5-fluorouracil impact, and complications.<BR>One hundred fifty-seven patients underwent trab-MMC and 47 underwent XGS AEO. Groups had similar baseline intraocular pressure (IOP) and medications (meds). Intraocular pressure and meds decreased similarly at 1.5 years (11.2 mmHg vs. 7.4 mmHg, P = 0.62; 2.9 vs. 2.8 meds, P = 0.92, respectively for trab-MMC and XGS AEO). Success was defined as IOP reduction ≥ 20% with 5 mmHg ≤ IOP ≤ 18 mmHg for 2 consecutive visits. Complete success (CS) did not allow meds; qualified success (QS) allowed for ≤ baseline meds. When IOP fluctuations in the first 60 days were not counted as failures, CS was 43% for trab-MMC, about 8.5% higher than for XGS AEO (P < 0.01). Qualified success was similar between the groups (65%-67%). Procedure time was shorter for XGS AEO than trab-MMC (44 vs. 63 minutes, P < 0.01).<BR>XEN45 Gel Stent AEO may provide similar benefits to trab-MMC, especially for patients who tolerate some meds, with shorter procedure times.<BR>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.